SAB Biotherapeutics, Inc. (SABSW) stock
SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
$0.01+0.00 (+33.33%)
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
SAB Biotherapeutics operating margin
Operating margin is operating income as a percentage of revenue.
SAB Biotherapeutics's operating margin for the twelve months ending Dec 31, 2024 was -3244.9%. For fiscal 2024 it was -3244.9%, against -1700.6% the year before. The highest annual figure on record is 37.2% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -3244.9% | −1544.3 |
| FY2023 | Dec 31, 2023 | -1700.6% | −1579.6 |
| FY2022 | Dec 31, 2022 | -121.0% | −99.0 |
| FY2021 | Dec 31, 2021 | -22.0% | −59.2 |
| FY2020 | Dec 31, 2020 | 37.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -8726.3% | −8306.3 |
| Q2 FY2024 | Jun 30, 2024 | -3877.0% | +3696.4 |
| Q1 FY2024 | Mar 31, 2024 | -1205.9% | +67.9 |
| Q4 FY2023 | Dec 31, 2023 | -6187.9% | −5824.2 |
| Q3 FY2023 | Sep 30, 2023 | -420.0% | −202.5 |
| Q2 FY2023 | Jun 30, 2023 | -7573.4% | −7470.4 |
| Q1 FY2023 | Mar 31, 2023 | -1273.8% | −1217.0 |
| Q4 FY2022 | Dec 31, 2022 | -363.7% | −297.3 |
| Q3 FY2022 | Sep 30, 2022 | -217.5% | −190.3 |
| Q2 FY2022 | Jun 30, 2022 | -103.0% | −87.3 |
| Q1 FY2022 | Mar 31, 2022 | -56.8% | −61.6 |
| Q4 FY2021 | Dec 31, 2021 | -66.4% | – |
| Q3 FY2021 | Sep 30, 2021 | -27.2% | – |
| Q2 FY2021 | Jun 30, 2021 | -15.8% | – |
| Q1 FY2021 | Mar 31, 2021 | 4.8% | – |